Genomes and Genes
Summary: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
Publications257 found, 100 shown here
- Once-daily, high-concentration MMX mesalamine in active ulcerative colitisMichael A Kamm
Department of Gastroenterology, St Mark s Hospital, Watford Road, Harrow, United Kingdom
Gastroenterology 132:66-75; quiz 432-3. 2007SPD476 (LIALDA in the US; MEZAVANT in the EU; otherwise known as MMX mesalamine; Shire Pharmaceuticals Inc., Wayne, PA, under license from Giuliani SpA, Milan, Italy) is a novel, once-daily, high-strength (1...
- PPARgamma as a new therapeutic target in inflammatory bowel diseasesL Dubuquoy
INSERM U795 ex E114, Clinique des maladies de l appareil digestif et de la nutrition, Hôpital Swynghedauw, Rue A Verhaeghe, F 59037 Lille Cedex, France
Gut 55:1341-9. 2006..The aims of this review are to discuss the potential roles of PPARgamma in the physiopathology of IBD, as well as the emerging therapeutic strategies targeting this receptor...
- Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitisS Fiorucci
Department of Gastroenterology, University of Perugia, Perugia, Italy
Br J Pharmacol 150:996-1002. 2007b>Mesalamine is the first-line therapy for colitis, but it lacks potency and is only effective for mild-to-moderate forms of this disease...
- Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitisJeffrey B Brown
Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children s Memorial Hospital, Northwestern University, Feinberg School of Medicine, Chicago, Illinois 60611, USA
Gastroenterology 138:595-605, 605.e1-3. 2010b>Mesalamine is a mainstay therapeutic agent in chronic ulcerative colitis (CUC) in which condition it reverses crypt architectural changes and reduces colitis-associated cancer (CAC)...
- Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestationsRuni A Foster
Department of Medicine, University of Florida College of Medicine, Gainesville, Florida 32610, USA
Inflamm Bowel Dis 9:308-15. 2003Lung injury related to mesalamine (5-aminosalicylic acid) has rarely been reported in patients with inflammatory bowel diseases...
- Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studiesFernando S Velayos
Division of Gastroenterology and UCSF Center for Colitis and Crohn s Disease, University of California, San Francisco, California 94143, USA
Am J Gastroenterol 100:1345-53. 2005..We performed a systematic review with metaanalysis of observational studies evaluating the association between 5-ASA use and colorectal cancer (CRC) or dysplasia among patients with ulcerative colitis...
- 5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based studyCharles N Bernstein
University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, Winnipeg, Manitoba, Canada
Am J Gastroenterol 106:731-6. 2011..We aimed to determine if use of 5-aminosalicylates (5-ASA) was associated with a reduced risk of colorectal cancer (CRC) in people with inflammatory bowel disease (IBD)...
- Medications as a source of human exposure to phthalatesRuss Hauser
Department of Environmental Health, Occupational Health Program, Harvard School of Public Health, Boston, Massachusetts 02115, USA
Environ Health Perspect 112:751-3. 2004..we report on medications as a potential source of exposure to DBP in a man who took Asacol [active ingredient mesalamine (mesalazine)] for the treatment of ulcerative colitis...
- Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept studyR Corinaldesi
Department of Clinical Medicine and Center for Applied Biomedical Research, University of Bologna, Bologna, Italy
Aliment Pharmacol Ther 30:245-52. 2009..Intestinal immune infiltration contributes to symptoms in patients with irritable bowel syndrome (IBS)...
- Systematic review: adherence issues in the treatment of ulcerative colitisS V Kane
Section of Gastroenterology, Department of Medicine, The University of Chicago, Chicago, IL, USA
Aliment Pharmacol Ther 23:577-85. 2006..It is a combination of understanding patient behaviour, recognizing signs of non-adherent behaviour and utilizing management strategies to change behaviour that will improve patient outcomes...
- Mesalamine protects against colorectal cancer in inflammatory bowel diseaseJeffrey Tang
Department of Internal Medicine, Division of Gastroenterology, Henry Ford Health System, Henry Ford Hospital, Detroit, MI 48202, USA
Dig Dis Sci 55:1696-703. 2010..Previous studies show this risk is strongly associated with dysplasia, extent of disease, duration of disease, and degree of inflammation, while chemoprevention of CRC has less support...
- Systematic review: molecular chemoprevention of colorectal malignancy by mesalazineA Lyakhovich
Department of Medicine, Medical University of Vienna, Austria
Aliment Pharmacol Ther 31:202-9. 2010Mesalazine (mesalamine) (5-ASA) is considered an anti-inflammatory drug for the treatment of inflammatory bowel disease. It is well tolerated by most patients and induces mucosal healing specifically in ulcerative colitis...
- Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazideP W Lowry
Division of Gastroenterology, Division of Clinical Pharmacology, Department of Pharmacology, and Section of Biostatistics, Mayo Clinic, Rochester, MN, USA
Gut 49:656-64. 2001AIM: We evaluated the effect of coadministration of sulphasalazine, mesalamine, and balsalazide on the pharmacokinetics and pharmacodynamics of azathioprine and 6-mercaptopurine...
- Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitisWilliam J Sandborn
Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
Gastroenterology 137:1934-43.e1-3. 2009It is not clear what induction dose of mesalamine is optimal for treating patients with mildly and moderately active ulcerative colitis (UC). This study was conducted to determine the efficacy and safety of mesalamine 4...
- Inflammatory bowel disease: clinical aspects and established and evolving therapiesDaniel C Baumgart
Department of Medicine, Division of Gastroenterology and Hepatology, Charité Medical Centre, Virchow Hospital, Medical School of the Humboldt University of Berlin, 13344 Berlin, Germany
Lancet 369:1641-57. 2007..Finally, we summarise the practical aspects of standard therapies including dosing, precautions, and side-effects...
- Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitisMatthew Rutter
Department of Gastroenterology, University Hospital of North Tees, Stockton on Tees, Teesside, England
Gastroenterology 126:451-9. 2004..Patients with ulcerative colitis are at increased risk of colorectal cancer. It is widely believed that this is secondary to colonic inflammation. However, the severity of colonic inflammation has never been shown to be a risk factor...
- 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivityEleonora Distrutti
Clinica di Gastroenterologia, Policlinico Monteluce, University of Perugia, Via Enrico Dal Pozzo, 06122 Perugia, Italy
J Pharmacol Exp Ther 319:447-58. 2006..In this study, we have investigated the role of a novel H(2)S-releasing derivative of mesalamine (5-amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester, ATB-429) in modulating nociception ..
- Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitisWilliam J Sandborn
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55905, USA
Gastroenterology 138:1286-96, 1296.e1-3. 2010..This study was conducted to determine the efficacy and safety of once-daily dosing of delayed-release mesalamine (Asacol 400-mg tablets) compared with twice-daily dosing for maintaining remission in UC patients.
- Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flaresP D R Higgins
Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA
Aliment Pharmacol Ther 29:247-57. 2009..Ulcerative colitis (UC) can be maintained in remission with 5-aminosalicylic acid (5-ASA) medications, but frequent non-adherence by patients who are feeling well has been associated with more frequent flares of colitis...
- Nonadherence in inflammatory bowel disease: results of factor analysisPetr Cerveny
Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Kralove, Charles University, Prague, Czech Republic
Inflamm Bowel Dis 13:1244-9. 2007..The purpose of the study was to assess overall nonadherence to treatment among patients with Crohn's disease (CD) and ulcerative colitis (UC) in a single tertiary center...
- Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activityCarina L Bos
Laboratory of Experimental Oncology and Radiobiology, Department of Oncology, University of Amsterdam, The Netherlands
Carcinogenesis 27:2371-82. 2006..This study shows, using concentrations of mesalazine identical to concentrations seen in patients with inflammatory bowel disease, that mesalazine inhibits the Wnt/beta-catenin pathway via inhibition of PP2A...
- Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gammaChristel Rousseaux
Institut National de la Santé et de la Recherche Medicale 0114, Physiopathologie des Maladies Inflammatoires Intestinales, CHU 59037 Lille, France
J Exp Med 201:1205-15. 2005..Validation of these results was obtained with organ cultures of human colonic biopsies. These data identify PPAR-gamma as a target of 5-ASA underlying antiinflammatory effects in the colon...
- Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugsS G Nugent
Department of Surgery, St George's Hospital Blackshaw Road, London, UK
Gut 48:571-7. 2001..This paper reviews methods for measuring gut pH, its changes in IBD, and how these may influence current and future therapies...
- 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitisMargie L Clapper
Division of Population Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Inflamm Bowel Dis 14:1341-7. 2008..The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis-associated neoplasia...
- Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cellsA Reinacher-Schick
Department of Medicine, Ruhr University Bochum, Knappschaftskrankenhaus, Germany
Carcinogenesis 24:443-51. 2003..These findings may suggest a potential of mesalazine as a chemopreventive agent for colorectal cancer...
- Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitisMichael A Kamm
St Vincent s Hospital, Department of Medicine, University of Melbourne, Melbourne, Australia
Inflamm Bowel Dis 15:1-8. 2009Many patients with ulcerative colitis (UC) respond to mesalamine therapy within 8 weeks. Those not achieving remission after 8 weeks are often treated with steroids or other immunosuppressive therapies...
- Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitisPaul L McCormack
Wolters Kluwer Health Adis, Auckland, New Zealand, an editorial office of Wolters Kluwer Health, Conshohocken, Pennsylvania, USA
Drugs 67:2635-42. 2007..Two of 434 MMX mesalazine recipients experienced serious adverse events that were considered treatment related (pancreatitis caused by mesalazine sensitivity)...
- Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent diseaseReikei Matsuda
Department of Internal Medicine, Fujisawa Shounandai Hospital, Fujisawa, Kanagawa, Japan
Inflamm Bowel Dis 15:328-34. 2009..This study was to investigate the expressions of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-8, and IL-10 mRNAs in the colonic mucosa of patients with ulcerative colitis (UC) during active and quiescent UC...
- Mesalamine delivery systems: do they really make much difference?Altamash I Qureshi
Department of Internal Medicine, Wayne State University, Detroit Medical Center, USA
Adv Drug Deliv Rev 57:281-302. 2005..aminosalicylates, which eliminate the sulfa-moiety, and attempt to target the topically active mesalamine to the inflamed bowel...
- Development and in vitro evaluation of mesalamine delayed release pellets and tableted reservoir-type pelletsEhab R Bendas
Department of Pharmaceutics, College of Pharmacy, Oregon State University, Corvallis, OR, USA
Drug Dev Ind Pharm 36:393-404. 2010..The basic objective of this study was to develop a novel technique that aids in compaction of coated pellets into tablets and obtain a release pattern from compressed pellets resembling the same pattern before compression...
- Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitisW Kruis
Evangelisches Krankenhaus Kalk, University of Cologne, Germany
Aliment Pharmacol Ther 33:313-22. 2011Comparative data regarding different regimens of oral mesalazine (mesalamine) for maintaining remission in ulcerative colitis are limited.
- Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteersW J Sandborn
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Aliment Pharmacol Ther 19:1089-98. 2004Existing pharmacokinetic data are insufficient to determine whether a delayed-release formulation of mesalamine (Asacol) results in greater systemic exposure to 5-aminosalicylic acid and its major metabolite N-acetyl-5-aminosalicylic acid ..
- Current concept of pathophysiological understanding and natural course of ulcerative colitisMartin H Holtmann
Department of Medicine, Johannes Gutenberg University, Langenbeckstrasse 1, 55131 Mainz, Germany
Langenbecks Arch Surg 389:341-9. 2004....
- Once daily 5-aminosalicylic acid for the treatment of ulcerative colitis; are we there yet?Peter Laszlo Lakatos
1st Department of Medicine, Semmelweis University, Koranyi S 2A, H 1083 Budapest, Hungary
Pharmacol Res 58:190-5. 2008..In this systematic review, the authors summarize the available literature on the short- and medium-term efficacy and safety of the new once daily mesalazine formulations...
- Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled studyFabrizio Bossa
UU OO Gastroenterologia ed Endoscopia Digestiva, Ospedale Casa Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo, Italy
Am J Gastroenterol 103:2509-16. 2008..We planned a controlled study to investigate the efficacy and safety of dexamethasone 21-P (Dex 21-P) encapsulated into erythrocytes (DEE)...
- Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitisSunanda Kane
Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Inflamm Bowel Dis 18:1026-33. 2012..to assess clinical recurrence in patients with ulcerative colitis (UC) who received maintenance treatment with MMX Multi Matrix System (MMX) mesalamine. A secondary outcome was the relationship between long-term efficacy and adherence.
- Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouseS R Ritland
Department of Biochemistry and Molecular Biology, Mayo Clinic Scottsdale, Arizona 85259, USA
Clin Cancer Res 5:855-63. 1999....
- Mesalazine inhibits the beta-catenin signalling pathway acting through the upregulation of mu-protocadherin gene in colo-rectal cancer cellsS Parenti
Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy
Aliment Pharmacol Ther 31:108-19. 2010..A recent observation has suggested that inhibition of beta-catenin signalling could induce these cellular effects...
- Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteersThai Hoa Joeres-Nguyen-Xuan
Evangelisches Krankenhaus Kalk, Cologne, Germany
Inflamm Bowel Dis 16:256-62. 2010b>Mesalamine and the probiotic E. coli Nissle 1917 (EcN) are both effective agents for the treatment of ulcerative colitis. A combined therapy may have more than additive efficacy. However, mesalamine may have antimicrobial effects on EcN.
- One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitisA Barney Hawthorne
Department of Medicine, University Hospital of Wales, Cardiff, UK
Inflamm Bowel Dis 18:1885-93. 2012..We aimed to investigate whether OD Asacol was as effective as three times (TDS) daily dosing, and to evaluate the role of treatment adherence...
- The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the β-catenin signaling pathwayJohanna Munding
Institute of Pathology, Ruhr University Bochum, D 44789, Germany
Carcinogenesis 33:637-43. 2012..Therefore, we suggest the use of 5-ASA as a promising drug for prevention of sporadic colorectal carcinoma...
- Small intestinal release mesalamine for the treatment of refractory celiac disease type IShailaja Jamma
Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
J Clin Gastroenterol 45:30-3. 2011The goal of this study is to evaluate the safety and efficacy of Small intestinal release mesalamine (SIRM) for symptom relief in refractory celiac disease (RCD).
- Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trialB J Rembacken
Centre for Digestive Diseases, The General Infirmary at Leeds, UK
Lancet 354:635-9. 1999..coli (Nissle 1917) was as effective as mesalazine in preventing relapse of ulcerative colitis. We also examined whether the addition of E. coli to standard medical therapy increased the chance of remission of active ulcerative colitis...
- Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's diseaseA Prakash
Adis International Limited, Mairangi Bay, Auckland, New Zealand
Drugs 57:383-408. 1999..4 g/day is effective in preventing postoperative recurrence of Crohn's disease. Oral delayed-release mesalazine is effective and well tolerated in sulfasalazine-intolerant patients with ulcerative colitis or Crohn's disease...
- Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized studyHiroaki Ito
Digestive Disease Center of Excellence, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan
Inflamm Bowel Dis 16:1567-74. 2010b>Mesalamine is the first-line drug for the treatment of ulcerative colitis (UC). We directly compared the efficacy and safety of two mesalamine formulations for the induction of remission in patients with UC.
- Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescentsMelvin B Heyman
Department of Pediatrics, University of California, San Francisco, California 94143 0136, USA
Inflamm Bowel Dis 16:1931-9. 2010..We conducted an open-label trial to evaluate the clinical efficacy of a mesalamine suppository (500 mg) to treat pediatric patients with mild to moderate ulcerative proctitis.
- Clinical pharmacokinetics of slow release mesalazineM De Vos
Department of Gastroenterology, Ghent University Hospital, Belgium
Clin Pharmacokinet 39:85-97. 2000..Although preliminary data support an association between mucosal concentrations of mesalazine and its clinical activity, further studies are needed to correlate the effects of this drug with its pharmacokinetic parameters...
- Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysisAlexander C Ford
Leeds Gastroenterology Institute, Leeds General Infirmary, UK
Am J Gastroenterol 106:2070-7; quiz 2078. 2011..Once-daily dosing may improve adherence, but impact on the relapse of disease activity is unclear as no previous meta-analysis has studied this issue...
- Mesalamine for inflammatory bowel disease: recent reappraisalsGiovanni C Actis
Department of Gastro Hepatology, Ospedale Gradenigo, Torino, Italy
Inflamm Allergy Drug Targets 7:1-5. 2008Derived from the historical molecule sulfasalazine, mesalamine has remained one of the mainstays for treatment of inflammatory bowel disease in the last 50 years...
- Mesalamine derivatives in the treatment of Crohn's diseaseLaura E Harrell
Section of Gastroenterology and Nutrition, University of Chicago Medical Center, 5841 South Maryland Avenue, MC 4076, Chicago, IL 60637, USA
Gastroenterol Clin North Am 33:303-17, ix-x. 2004..It remains to be determined whether certain high-risk groups of patients may benefit from higher doses of mesalamine induction or maintenance therapy. Mesalamine derivatives are also of benefit in the treatment of Crohn's disease...
- Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemopreventionWilliam J Sandborn
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
Rev Gastroenterol Disord 6:97-105. 2006Sulfasalazine, olsalazine, balsalazide, delayed-release mesalamine, controlled-release mesalamine, mesalamine pellets, and Multi-Matrix System mesalamine are effective first-line therapies for the treatment of mildly to moderately active ..
- Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitisL P Piodi
U O di Gastroenterologia, Servizio di Medicina Nucleare, Milan, Italy
Scand J Gastroenterol 39:154-7. 2004..Both the efficacy of long-term intermittent therapy with low-dose 5-ASA enemas in preventing UC relapses and its economic implications were evaluated...
- The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamineWolfgang Kruis
Evangelisches Krankenhaus Kalk, University of Cologne, Cologne, Germany
Clin Gastroenterol Hepatol 1:36-43. 2003..A new pellet preparation was designed combining slow and delayed release properties. Aims of the study were to find the optimal dose and to test efficacy and safety of a new 5-aminosalicylic acid formulation...
- Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trialStephen B Hanauer
Department of Medicine, University of Chicago Medical Center, Chicago, Illinois, USA
Gastroenterology 127:723-9. 2004..The aim of the current trial was to compare 6-mercaptopurine (6-MP) and mesalamine with placebo for the prevention of clinical, endoscopic, and radiographic recurrence of Crohn's disease after ..
- Diagnosis and treatment of ulcerative proctitisMiguel D Regueiro
Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh School of Medicine, Pennsylvania 15212, USA
J Clin Gastroenterol 38:733-40. 2004..This review highlights the pathogenesis, diagnosis, and treatment of ulcerative proctitis...
- Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trialsMiguel Regueiro
Inflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
Inflamm Bowel Dis 12:979-94. 2006..The results of this review provided the content for the accompanying treatment guidelines, Clinical Guidelines for the Medical Management of Left-sided Ulcerative Colitis and Ulcerative Proctitis: Summary Statement...
- Ulcerative proctitis: a review of pharmacotherapy and managementPeter Laszlo Lakatos
Semmelweis University, First Department of Medicine, H1083 Budapest, Koranyi S 2A, Hungary
Expert Opin Pharmacother 9:741-9. 2008..Ulcerative proctitis (UP) is a common presentation of ulcerative colitis (UC)...
- A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitisJohn I Mackowiak
Center for Outcomes Research, Chapel Hill, North Carolina 27517, USA
Manag Care Interface 19:39-46, 56. 2006..results from clinical trials directly comparing oral balsalazide capsules and a specific formulation of oral mesalamine. Health care costs related to UC for an oral 5-ASA failure is greater than dollar 11,500 on average in the first ..
- Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylatesJoel H Rubenstein
The Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA
Am J Gastroenterol 104:2222-32. 2009..Therefore, in patients prescribed 5-ASAs for maintenance of remission, annual surveillance might be overly burdensome and inefficient. We aimed to determine the ideal frequency of surveillance in patients with UC maintained on 5-ASAs...
- Comparative absorption of 5-aminosalicylic acid (5-ASA) after administration of a 5-ASA enema and salazosulfapyridine (SASP) after an SASP suppository in Japanese volunteersKenji Tokui
Department of Pharmacy, Nagoya Daini Red Cross Hospital, Japan
Biol Pharm Bull 25:264-7. 2002..The present findings suggest that 5-ASA has favorable absorptive properties and can be expected to have systemic action after rectal administration of a 5-ASA enema...
- A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspectiveNic Brereton
School of Health and Related Research ScHARR, The University of Sheffield, Regent Court, 30 Regent Street, Sheffield, UK
J Med Econ 13:148-61. 2010..To perform a cost-utility analysis of a new formulation of mesalazine (Mezavant XL, MMX mesalazine) versus an existing oral mesalazine (Asacol; mesalazine) from the UK National Health Service perspective...
- Mono- and biphasic plasma concentration-time curves of mesalazine from a 500 mg suppository in healthy male volunteers controlled by the time of defecation before dosingT B Vree
Institute for Anaesthesiology, Academic Hospital Nijmegen Sint Radboud, Nijmegen, The Netherlands
J Pharm Pharmacol 52:645-52. 2000..8% metabolite with I and 15.5% with II. The renal clearance of the metabolite acetylmesalazine was independent of the observed defecation patterns (300 mL min(-1), P > 0.8), stool composition, and type of absorption...
- Inhibition of colon carcinogenesis by 2-methoxy-5-amino-N-hydroxybenzamide, a novel derivative of mesalamineCarmine Stolfi
Department of Internal Medicine, University of Tor Vergata, Rome, Italy
Gastroenterology 138:221-30. 2010b>Mesalamine has been reported to protect against inflammatory bowel disease-related colorectal cancer (CRC), but several drug-related issues have limited its use in chemopreventive programs...
- Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acidCarmine Stolfi
Dipartimento di Medicina Interna, Universita Tor Vergata, Via Montpellier, 1 00133 Rome, Italy
Biochem Pharmacol 75:668-76. 2008..Taken together our data indicate that 5-ASA causes both a COX-2-dependent and -independent inhibition of CRC cell growth...
- Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitisAntonio Tursi
Digestive Endoscopy Unit, Lorenzo Bonomo Hospital, Andria BA, Italy
Med Sci Monit 10:PI126-31. 2004..25 g/day) plus 3 g/day VLS#3 (group A) with medium-dose balsalazide alone (group B) and with mesalazine (group C) in the treatment of mild-to-moderate active ulcerative colitis...
- Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitisAntoine Cortot
Gastroenterologie, Hopital Claude Huriez, Lille, France
Am J Gastroenterol 103:3106-14. 2008To determine in a noninferiority study whether mesalamine foam is as effective as mesalamine liquid enema for inducing clinical remission in patients with active left-sided ulcerative colitis (UC).
- Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costsWilliam N Tindall
Department of Family Medicine, Wright State University, Dayton, Ohio, USA
J Manag Care Pharm 13:S2-12; quiz S13-4. 2007..Continued disease progression and relapse of UC over time are associated with an increased risk of colorectal cancer (CRC)...
- Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteersM Brunner
Department of Clinical Pharmacology, Division of Clinical Pharmacokinetics, University of Vienna Medical School, Vienna, Austria
Aliment Pharmacol Ther 17:1163-9. 2003..Mesalazine (5-aminosalicylic acid)-containing formulations, designed to optimize drug delivery to the ileo-caecal region, represent a cornerstone in the treatment of inflammatory bowel diseases...
- Management of distal ulcerative colitis: frequently asked questions analysisS L James
Department of Gastroenterology and Monash University Department of Medicine, Box Hill Hospital, Melbourne, Victoria, Australia
Intern Med J 38:114-9. 2008..The changes in guidelines have raised several management questions, many of which are addressed in this review...
- Prevention by intrarectal 5-aminosalicylic acid of N-methylnitrosourea-induced colon cancer in F344 ratsTomio Narisawa
Akita University College of Allied Medical Sciences, Hondo, Japan
Dis Colon Rectum 46:900-3. 2003..The protective effect of 5-aminosalicylic acid against colon carcinogenesis was investigated...
- Reduction of peroxisome proliferation-activated receptor gamma expression by gamma-irradiation as a mechanism contributing to inflammatory response in rat colon: modulation by the 5-aminosalicylic acid agonistChristine Linard
Institut de Radioprotection et de Surete Nucleaire, Direction de la RadioProtection de l Homme, Laboratoire de Radiopathology, B P no 17, F 92262 Fontenay aux Roses Cedex, France
J Pharmacol Exp Ther 324:911-20. 2008..Collectively, these results indicate that PPAR agonists may be effective in the prevention of inflammatory processes and immune responses during and after pelvic radiotherapy...
- Aminosalicylic acid inhibits IkappaB kinase alpha phosphorylation of IkappaBalpha in mouse intestinal epithelial cellsF Yan
Department of Pediatrics, Division of Gastroenterology and Nutrition, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
J Biol Chem 274:36631-6. 1999..These findings suggest a novel role for 5-ASA in the management of IBD by disrupting TNFalpha activation of NFkappaB...
- Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic propertiesA Tromm
Department of Gastroenterology and Hepatology, BG Kliniken Bergmannsheil University Clinic, Bochum, Germany
Hepatogastroenterology 46:3124-35. 1999..However, the distinct therapeutic goal (acute phase treatment, maintenance therapy or post-operative prophylaxis), the involved areas of the gut and the specific release of the drug administered have to be considered...
- [5-aminosalicylates and colorectal cancer: preventive role in chronic inflammatory bowel disease?]Pierre Desreumaux
Service des maladies de l appareil digestif et de la nutrition, Equipe INSERM Université 0114, CHU Lille
Gastroenterol Clin Biol 28:509. 2004
- Effects of mesalamine (5-aminosalicylic acid) on bacterial gene expressionJaime Kaufman
Department of Medicine, Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada
Inflamm Bowel Dis 15:985-96. 2009..In an effort to better understand the bacteriological effects of 5-ASA, we examined the role of this compound at the level of bacterial gene expression...
- Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational studyJ R B Green
Gastroenterology Unit, City General Hospital, Stoke on Trent, UK
Aliment Pharmacol Ther 19:435-42. 2004..The patient-centred approach is new to the management of ulcerative colitis. To date, it has only been shown to be successful in a short-term study...
- Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitisRonald Pruitt
Vanderbilt University School of Medicine, Nashville Medical Research Institute, Nashville, Tennessee, USA
Am J Gastroenterol 97:3078-86. 2002..The study objective was to compare symptomatic remission rates with balsalazide and mesalamine while controlling for extent of disease and time since diagnosis in patients with active, mild-to-moderate ..
- Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamineXiaoming Deng
Diagnostic and Molecular Medicine, Health Care Groups, VA Medical Center, Long Beach, California 90822, USA
J Pharmacol Exp Ther 331:1071-8. 2009b>Mesalamine (5-aminosalicylate acid, 5-ASA) is an effective treatment for ulcerative colitis (UC). The mechanisms of its actions are not fully understood...
- Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazineW Kruis
Evangelisches Krankenhaus Kalk, University of Cologne, Germany
Gut 53:1617-23. 2004..We compared the efficacy in maintaining remission of the probiotic preparation Escherichia coli Nissle 1917 and established therapy with mesalazine in patients with ulcerative colitis...
- Effectiveness of mesalamine and propolis in experimental colitisAhmet Aslan
Department of General Surgery, Mustafa Kemal University, Antakya Hatay, Turkey
Adv Ther 24:1085-97. 2007This study was conducted to investigate the effects of propolis and mesalamine on experimental colitis in rats. Distal colitis was induced in rats by intracolonic instillation of 2 mL of 4% acetic acid...
- Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitisS B Hanauer
Professor of Medicine and Clinical Pharmacology Chief, Section of Gastroenterology, Hepatology and Nutrition, University of Chicago, 5841 S Maryland Ave, MC 4076, Chicago, IL 60637, USA
Aliment Pharmacol Ther 24:37-40. 2006..6 g/day of mesalazine, although the absence of dose-related side effects allows continuation of the same inductive dose through maintenance treatment without dose-related toxicity...
- MMX mesalamineDanial E Baker
College of Pharmacy, Washington State University, Spokane, Washington, USA
Rev Gastroenterol Disord 6:146-52. 2006..The pharmaceutical industry has been developing different delivery systems for Multi-Matrix System (MMX) mesalamine for the treatment of Crohn's disease and ulcerative colitis...
- 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpointM Gloria Luciani
Medical University of Vienna, Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Wahringer Gurtel 18, A 1090 Vienna, Austria
Gastroenterology 132:221-35. 2007..In this study, we hypothesized that 5-ASA restrains cell cycle progression by activating checkpoint pathways in colorectal cell lines, which would prevent tumor development and improve genomic stability...
- The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agentHillel D Cohen
Department of Gastroenterology and Hepatology, Crohn s and Colitis Center of New Jersey, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
J Clin Gastroenterol 40:S150-4. 2006..Several recent studies have evaluated the use of 5-ASA drugs (mesalamine) for the treatment of uncomplicated acute diverticulitis...
- Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamineSreedhar Subramanian
Division of Gastroenterology, University School of Clinical Science, Liverpool, UK
Inflamm Bowel Dis 14:162-75. 2008..Mucosally adherent E. coli are found in inflammatory bowel disease (IBD) and colon cancer. They promote release of the proinflammatory cytokine interleukin-8 (IL-8). We explored mechanisms for this release and its inhibition by drugs...
- Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trialStephen B Hanauer
Division of Gastroenterology, University of Chicago Medical Center, Chicago, Illinois 60637, USA
Am J Gastroenterol 100:2478-85. 2005Preliminary data have shown that delayed release oral mesalamine (Asacol) dosed at 4.8 g/day provided additional efficacy benefit compared to 1.6 g/day in patients with mildly to moderately active ulcerative colitis...
- Mesalamine promotes intestinal epithelial wound healing in vitro through a TGF-beta-independent mechanismDaniel C Baumgart
Department of Medicine, Division of Hepatology and Gastroenterology, Charite Medical Center Virchow Hospital, Medical School of the Humboldt University of Berlin, Germany
Scand J Gastroenterol 40:958-64. 2005..The aim of this study was to investigate whether 5-ASA also modulates intestinal epithelial wound repair in vitro...
- Mesalazine improves replication fidelity in cultured colorectal cellsChristoph Gasche
Department of Medicine 4, Division of Gastroenterology and Hepatology, Medical University Vienna, Vienna, Austria
Cancer Res 65:3993-7. 2005..This finding suggests that mesalazine improves replication fidelity, an effect that may be active in reducing mutations independent of its anti-inflammatory properties...
- A new oral delivery system for 5-ASA: preliminary clinical findings for MMxCosimo Prantera
Department of Gastroenterology, Azienda Ospedaliera S Camillo Forlanini, Rome, Italy
Inflamm Bowel Dis 11:421-7. 2005..This study had 2 objectives: (1) to evaluate the therapeutic response to MMx in patients with active left-sided disease and (2) to gain additional insights as to how the therapy would compare with topical 5-ASA...
- Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitisGary R Lichtenstein
Division of Gastroenterology, University of Pennsylvania, Philadelphia, Pennsylvania 19104 4283, USA
Clin Gastroenterol Hepatol 5:95-102. 2007SPD476 (MMX mesalamine), a novel, once-daily mesalamine formulation, uses MMX Multi Matrix System (MMX) technology to delay and extend delivery of active drug throughout the colon...
- 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel diseaseJonathan P Terdiman
University of California, San Francisco, San Francisco, California 94143 1623, USA
Inflamm Bowel Dis 13:367-71. 2007..The objective of this observational study was to determine if an association between 5-ASA therapy and CRC risk exists in IBD patients...
- Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in ratsJ L Wallace
Department of Pharmacology and Therapeutics, University of Calgary, Calgary, Alberta, Canada
Gastroenterology 117:557-66. 1999..We evaluated whether a similar derivatization of mesalamine (5-aminosalicylic acid) would improve its anti-inflammatory activity.
- Possible mesalamine-induced pericarditis: case report and literature reviewRobert A Waite
Department of Pharmacy Practice, Nesbitt School of Pharmacy, Wilkes University, Wilkes Barre, Pennsylvania 18766, USA
Pharmacotherapy 22:391-4. 2002..be considered in any patient complaining of chest pain and/or dyspnea who is taking a product that contains mesalamine or sulfasalazine...
- Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitisP G Farup
, , Norway
Inflamm Bowel Dis 7:237-42. 2001..The patients preferred the twice daily dosing...
- Which 5-ASA?S P L Travis
John Radcliffe Hospital, Oxford OX3 9DU, UK
Gut 51:548-9. 2002
- Medication nonadherence and the outcomes of patients with quiescent ulcerative colitisSunanda Kane
Department of Medicine, University of Chicago, Chicago, Illinois 60637, USA
Am J Med 114:39-43. 2003We conducted a prospective study to determine the effects of nonadherence with mesalamine among patients with quiescent ulcerative colitis.
- Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acidCharles N Bernstein
Section of Gastroenterology, University of Manitoba Inflammatory Bowel Disease Clinical and Research Center, Winnipeg, Manitoba, Canada
Inflamm Bowel Dis 8:356-61. 2002..The scientific rationale for using these agents is sound but clinical data are lacking to fully support these approaches as chemoprevention in chronic colitis at present...
- Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitisS V Kane
Department of Medicine, University of Chicago, Illinois, USA
Am J Gastroenterol 96:2929-33. 2001..METHODS: Outpatients with clinically quiescent ulcerative colitis for >6 months on maintenance mesalamine (Asacol, Procter and Gamble, Cincinnati, OH) were eligible...
- A pilot trial of Saccharomyces boulardii in ulcerative colitisMario Guslandi
Gastroenterology Unit, S Raffaele University Hosptial, Milan, Italy
Eur J Gastroenterol Hepatol 15:697-8. 2003..The aim of this study was to assess the efficacy of S. boulardii in ulcerative colitis patients...
- Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel diseaseM J Shale
Department of Gastroenterology, Northern General Hospital, Sheffield Teaching Hospitals NHS Trust, Sheffield, UK
Aliment Pharmacol Ther 18:191-8. 2003..Non-compliance with maintenance mesalazine therapy may be a risk factor for relapse in inflammatory bowel disease, but the prevalence and determinants of non-compliance are unknown...
- Chemoprevention of colon cancer carcinogenesis by balsalazide: inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in the B6-Min/+ mouseD J MacGregor
GI Research Lab, VA Medical Center, San Francisco, CA, USA
Int J Oncol 17:173-9. 2000..BSZ produces a dose-dependent chemopreventive effect on colon carcinogenesis. A possible mechanism is consistent with the inhibition of cellular proliferation and the induction of apoptosis...
- Crossover Study on Human Exposure to Phthalates and Male FertilityRuss B Hauser; Fiscal Year: 2010..S. population. The source of DBP exposure was Asacol (mesalamine, with enteric coating containing DBP) used to treat inflammatory bowel disease (IBD)...
- 5ASA REGULATION OF MNSOD IN INTESTINAL CELLSJohn Valentine; Fiscal Year: 2002..The peak onset of IBD is between 15 and 25 years of age and the majority of patients with IBD are under age 40. Mesalamine (5-ASA) is the active ingredient in sulfasalazine and is one of the major therapies use to treat active disease ..
- Targeting Oxidative Stress in Chronic Beryllium DiseaseBrian Day; Fiscal Year: 2009..The studies will mechanistically target these changes with a novel therapeutic approach using 5 aminosalicylic acid in CBD subjects. ..
- Targeting Oxidative Stress in Chronic Beryllium DiseaseLisa A Maier; Fiscal Year: 2010..The studies will mechanistically target these changes with a novel therapeutic approach using 5 aminosalicylic acid in CBD subjects. ..
- Behavioral Treatment of Nonadherence in Pediatric Inflammatory Bowel DiseaseKEVIN HOMMEL; Fiscal Year: 2007..These evidence-based interventions should ultimately improve the effectiveness of health care and patient quality of life. ..
- Multi-site Trial of Azathioprine Dosing in Crohn DiseaseStephen Hanauer; Fiscal Year: 2004..Predictive models will be performed to assess responsiveness based upon initial and inducible TPMT activity and achievable 6-TGN and 6-MMPR metabolite based upon incremental AZA dosing. ..
- Dioxins and Male Pubertal Growth and DevelopmentRuss Hauser; Fiscal Year: 2009..The proposed study is unique since it will represent one of the first large longitudinal studies to explore the relationship of dioxins and PCBs with growth and development in pre-pubertal boys. ..
- Chemoprevention of Colitis-Associated Neoplasia by 5-ASAMARGIE CLAPPER; Fiscal Year: 2009..Findings from the proposed mouse studies could lead to the use of 5-ASA for cancer prevention and significantly impact the establishment of future guidelines for the clinical management of patients with inflammatory bowel disease. ..
- Maternal Pesticide Exposure and Pregnancy OutcomesRuss Hauser; Fiscal Year: 2009..Since the etiology of infertility and early pregnancy loss remains largely unexplained, the identification of potential environmental risk factors will have large public health significance. ..
- Trefoil Factors in GI Cancer BiologySteven Itzkowitz; Fiscal Year: 2009..The results of these studies could provide insights into novel treatment strategies for gastrointestinal malignancies. ..
- Dioxins and Male Pubertal Growth and DevelopmentRuss B Hauser; Fiscal Year: 2010..The proposed study is unique since it will represent one of the first large longitudinal studies to explore the relationship of dioxins and PCBs with growth and development in pre-pubertal boys. ..
- Adenosine in trauma and sepsisGyorgy Hasko; Fiscal Year: 2010....
- Chemoprevention of Colitis-Associated Neoplasia by 5-ASAMARGIE CLAPPER; Fiscal Year: 2009..Findings from the proposed mouse studies could lead to the use of 5-ASA for cancer prevention and significantly impact the establishment of future guidelines for the clinical management of patients with inflammatory bowel disease. ..
- Preventing Neoplastic Progression in Ulcerative ColitisThomas Ullman; Fiscal Year: 2007..abstract_text> ..
- Genetic Studies in Crohn's DiseaseJean Paul Achkar; Fiscal Year: 2007..The PI will continue to recruit patients and controls for an IBD DMA bank that he recently started. This collection will then be used to pursue a case-control, haplotype-based analysis of Paneth cell candidate genes. ..
- PCBs, Phthalates and Male Reproductive HealthRuss Hauser; Fiscal Year: 2007..Based on our results, the optimal exposure assessment strategy for the proposed study is to collect three urine samples from all subjects on day 1, 2 and 31 of their study participation. ..
- Clinical Approaches to Ileal Pouch DysfunctionBo Shen; Fiscal Year: 2005..The AIMS of study are to 1) investigate visceral hypersensitivity using barostat examination of the pouch; 2) conduct a randomized, placebo-controlled clinical trial evaluating the use of amitriptyline in IPS. ..
- IKK Beta In Intestinal InflammationLaurence Egan; Fiscal Year: 2005..abstract_text> ..
- Analysis of the Chemopreventive Activity of FGN 1MARGIE CLAPPER; Fiscal Year: 2004....
- TFF3 GENE EXPRESSION IN METASTATIC COLON CANCERSteven Itzkowitz; Fiscal Year: 2001..The use of the TFF3 gene to drive expression of suicide genes offers a novel approach which should result in more targetted, safer gene therapy for metastatic colon cancer. ..
- Pathologic Markers of Genetic Damage and Disease in IBDMelvin Heyman; Fiscal Year: 2005..abstract_text> ..
- Maternal Phthalate Exposure and Infertility, Fetal LossRuss Hauser; Fiscal Year: 2005..Since occupational and environmental exposure to phthalates is widespread, detecting even small adverse effects will have large public health significance. ..
- Test-Treat strategy to prevent ulcerative colitis relapseJames Lewis; Fiscal Year: 2007..The proposed study will test whether increasing mesalamine dose can reduce fecal calprotectin (FCP) levels, a marker of intestinal inflammation that is highly predictive ..
- Trefoil Factors in GI Cancer BiologySteven Itzkowitz; Fiscal Year: 2007..The results of these studies could provide insights into novel treatment strategies for gastrointestinal malignancies. ..
- OSCCAR: A Novel, Population-based Prospective Inception Cohort of Inflammatory BoBRUCE SANDS; Fiscal Year: 2007..We will follow these patients over time to determine the progression of their disease and to compare this to markers in the blood as a way of developing a system to predict the individual course of disease. ..
- Human Exposure to Bisphenol A, Phthalates and Fertility, Pregnancy OutcomesRuss Hauser; Fiscal Year: 2009..The proposed study will investigate associations of phthalates and BPA with male and female fertility and pregnancy outcomes. ..
- Phthalates in Drugs and Male Genital MalformationSonia Hernandez diaz; Fiscal Year: 2009....
- The Epidemiology of Adipokines in Barrett's EsophagusJoel Rubenstein; Fiscal Year: 2007..If so, measurement of these substances may be useful in a screening program. ..
- Comparative Effectiveness and Safety of Depression Treatments during PregnancySonia Hernandez diaz; Fiscal Year: 2010....
- Phthalates in Drugs and Male Genital MalformationAllen A Mitchell; Fiscal Year: 2010....
- IMMUNOMODULATION IN INFLAMMATORY BOWEL DISEASEBRUCE SANDS; Fiscal Year: 2004..The principal investigator seeks to become an independent clinical investigator by completing the didactic and scientific portions of this proposal. ..
- Assessment of Infant Outcomes After in Utero Exposure to Antiretroviral TherapySonia Hernandez diaz; Fiscal Year: 2010..We propose to evaluate the risk of congenital malformations and other adverse pregnancy outcomes following antenatal exposure to ART in a prospective cohort of pregnant women. ..
- IMURAN Dose Ranging Study in Crohn's DiseaseBRUCE SANDS; Fiscal Year: 2005..Abstract Not Provided ..
- Chemoprevention of Colitis-Associated Neoplasia by 5-ASAMargie L Clapper; Fiscal Year: 2010..Findings from the proposed mouse studies could lead to the use of 5-ASA for cancer prevention and significantly impact the establishment of future guidelines for the clinical management of patients with inflammatory bowel disease. ..